BRSYF (BrainsWay) ROCE %: 11.86% (As of Mar. 2026)

What is BrainsWay ROCE %?

BrainsWay BRSYF 70 ROCE % is 11.86% as of Mar. 2026. GuruFocus rates BRSYF with a GF Score™ of 70/100 and a GF Value™ of $6.71. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BrainsWay's annualized ROCE % for the quarter that ended in Mar. 2026 was 11.86%.

BrainsWay (OTCPK:BRSYF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BrainsWay ROCE % Related Terms

BrainsWay ROCE % Historical Data

* Premium members only.

The historical data trend for BrainsWay's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrainsWay ROCE % Chart

BrainsWay Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-13.55

-21.12

-7.12

5.43

9.76

BrainsWay Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															9.12	13.61	10.99	13.37	11.86

70GF Score

BrainsWay Ltd BRSYF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BrainsWay ROCE % Calculation

BrainsWay's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	8.277	/	( ( (94.316 - 15.346)	+	(113.191 - 22.495) )	/ 2 )
	=	8.277	/	( (78.97	+	90.696)	/ 2 )
	=	8.277	/	84.833
	=	9.76 %

BrainsWay's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	10.916	/	( ( (113.191 - 22.495)	+	(116.998 - 23.555) )	/ 2 )
	=	10.916	/	( ( 90.696	+	93.443 )	/ 2 )
	=	10.916	/	92.0695
	=	11.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 11.86% mean?

BrainsWay (BRSYF) has a ROCE % of 11.86% as of Mar. 2026.

Is BrainsWay's ROCE % too high?

BrainsWay's current ROCE % is 11.86%. The Medical Devices & Instruments industry median ROCE % is 2.23. BrainsWay's value of 11.86% is 431.8% above this industry median. Overall, BrainsWay has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.

How does BrainsWay's ROCE % compare to ABT and SYK?

BrainsWay's ROCE % of 11.86% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. BrainsWay's value of 11.86% is 431.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrainsWay's current ROCE % of 11.86% is 431.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrainsWay's current ROCE % is 11.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BrainsWay stock overvalued right now?

BrainsWay (BRSYF) has a current ROCE % of 11.86%. The stock's GF Value™ is $6.71, compared to a current price of $13.55 — trading 101.9% above its estimated fair value. The current ROCE % is 11.86% and 431.8% above the Medical Devices & Instruments industry median of 2.23. BrainsWay's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For BrainsWay (BRSYF), the current ROCE % is 11.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrainsWay (BRSYF) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of $13.55 is trading 101.9% above its estimated GF Value™ of $6.71.

Key valuation signals for BRSYF:

ROCE %: 11.86%
GF Value™: $6.71 vs. price of $13.55 (101.9% above fair value)
GF Score™: 70/100 with 3 warning signs
Industry Position: 431.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrainsWay Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XTAE:SOFW XTAE:ILX XTAE:ABOU XTAE:EPIT XTAE:PLSM XTAE:ALMD XTAE:ERKA XTAE:BIOV XTAE:EFNC-M XTAE:HUMX-M ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges BWAY:USA BWAY:Israel

Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516

Website https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

70GF Score

Get the complete analysis for BRSYF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.55

Price

$6.71

GF Value

View BRSYF Analysis

See ROCE % data for all stocks →